{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-039098","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2025-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.607324+00:00","generated_at":"2026-05-23T05:49:10.435075+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verastem raises $75M private placement for ovarian cancer drug launch and R&D","bullets":["Gross proceeds of ~$75M from sale of 3.43M shares at $7.00 and 7.29M pre-funded warrants at $6.9999.","Placement led by RTW Investments; includes BVF, Nantahala, Octagon, OrbiMed, Stonepine.","Net proceeds to fund potential launch of avutometinib/defactinib in LGSOC, R&D for VS-7375, and working capital.","Pre-funded warrants exercisable at $0.0001/share, no expiration; closing expected April 28, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-039098","json":"https://secwatch.observer/filing/0001104659-25-039098.json","markdown":"https://secwatch.observer/filing/0001104659-25-039098.md","text":"https://secwatch.observer/filing/0001104659-25-039098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925039098/0001104659-25-039098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925039098/tm2513177d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:49:10.435075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}